Morsy has been leading Rameda since its acquisition by a Compass Capital-led consortium in 2011. In July 2025, Rameda announced the acquisition of two products targeting CNS and pain management as well as generalized anxiety disorder. The combined markets for these products are valued at over $26 million with a three-year CAGR above 25%. In H1 2025, the company reported a 79% y-o-y increase in revenues reaching $37 million and had a total asset of nearly $100 million In September 2024, it launched Glow, a subsidiary producing affordable cosmetics and cosmeceuticals. Earlier in his career, Morsy served as Country Manager of Pfizer Egypt, which he joined in 1995.